A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 7, 2024

Primary Completion Date

November 1, 2024

Study Completion Date

November 15, 2024

Conditions
Healthy
Interventions
DRUG

Enlicitide

Participants will receive 20 mg enlicitide/180 mg sodium caprate coadministered with 0.25mg Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B.

DRUG

Digoxin

Participants will receive 0.25 mg digoxin orally on Day 1 Period 1 in Arm A and Day 1 Period 2 in Arm B. They also receive Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B coadministered with oral 20 mg enlicitide/180 mg sodium caprate.

Trial Locations (1)

68502

Celerion ( Site 0001), Lincoln

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY